Upload
Featured Recent Articles Topics Login Upload

Search Results for 'response pfs'

response pfs published presentations and documents on DocSlides.

Median PFS: 2.6 months (95% CI, 1.7-3.5)
Median PFS: 2.6 months (95% CI, 1.7-3.5)
by ceila
Median PFS: 1.4 months (95% CI, 1.2-1.6) . Median ...
Update on Diagnosis and Treatments
Update on Diagnosis and Treatments
by joanne
of Multiple Myeloma. Kenneth C. Anderson, M.D.. J...
ESMO 2021 (Virtual) Congress Report
ESMO 2021 (Virtual) Congress Report
by SnuggleBug
Lung and gastrointestinal cancers. Slide numbers. ...
Her-2 negative MBC
Her-2 negative MBC
by conchita-marotz
10/25/2016. Objectives. General principles. Endoc...
Btk inhibition in Mantle cell Lymphoma & CLL
Btk inhibition in Mantle cell Lymphoma & CLL
by test
Simon Rule. Professor of Clinical . Haematology. ...
Managing Advanced Renal Cell
Managing Advanced Renal Cell
by debby-jeon
Carcinoma: Balancing . Efficacy with Quality of L...
Summary 2011 Founded 2010
Summary 2011 Founded 2010
by eliza
in Houston. Vision: To be the leader in the develo...
GI CONNECT MEETING SUMMARY
GI CONNECT MEETING SUMMARY
by hanah
upper . gi. cancer HIGHLIGHTS . FROM ESMO 2022. D...
Meeting summary ASCO GU 2020,
Meeting summary ASCO GU 2020,
by patricia
San Francisco. , USA. Assoc. . Prof. . Shilpa Gupt...
Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat
Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat
by hadly
Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof C...
Updates on T-cell lymphoma
Updates on T-cell lymphoma
by grace3
Dr. Stefan K. Barta. University of Pennsylvania, U...
Molecular Lessons Learnt from Clinical Trials in the Last Decade
Molecular Lessons Learnt from Clinical Trials in the Last Decade
by altigan
Andrew X. Zhu, MD, PhD. Harvard Medical School. Ma...
Overall Survival Benefit of
Overall Survival Benefit of
by tatyana-admore
Obinutuzumab. Over Rituximab when Combined with ...
Immunotherapy for
Immunotherapy for
by sherrill-nordquist
High-Risk and Metastatic Melanoma. Timothy M. Kuz...
Impact of Imatinib interruption & duration of prior Hyd
Impact of Imatinib interruption & duration of prior Hyd
by pamella-moone
Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof ...
Novel
Novel
by tatiana-dople
Agents . for . Indolent . L. ymphoma . and . Mant...
MEK Inhibitors and their potential role in relapsed NSCLC
MEK Inhibitors and their potential role in relapsed NSCLC
by debby-jeon
Ranee Mehra, MD. Fox Chase Cancer Center. Philade...
Update on transplant-ineligible patients:
Update on transplant-ineligible patients:
by trish-goza
Which . regimens are best?. Suzanne Lentzsch MD, ...
Acquired Resistance Patient Forum
Acquired Resistance Patient Forum
by test
September 6, 2014 | Boston. In ALK, ROS1 & EG...
James Yang,
James Yang,
by pasty-toler
MD. The Evolving Treatment Landscape in NSCLC: Co...
The Impending D eath of Cancer: A Herculean Task Emerging Therapies 2016
The Impending D eath of Cancer: A Herculean Task Emerging Therapies 2016
by phoebe-click
The Impending D eath of Cancer: A Herculean Task...
Targeting endocrine-resistance pathways in breast cancer
Targeting endocrine-resistance pathways in breast cancer
by alexa-scheidler
Targeting endocrine-resistance pathways in breas...
by billiontins
2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...
Advances in Systemic Amyloidosis:
Advances in Systemic Amyloidosis:
by morton
A Spotlight on New Disease-Modifying . Therapies A...
The Impending D eath of Cancer:
The Impending D eath of Cancer:
by elina
A Herculean Task. Emerging Therapies 2016. Ruemu E...
Paolo Ghia, 1 Andrzej Pluta,
Paolo Ghia, 1 Andrzej Pluta,
by HappyHippo
2. Malgorzata Wach,. 3. Daniel Lysak,. 4. Tomas...
meeting summary Autumn 2021 MEETINGS in Multiple Myeloma
meeting summary Autumn 2021 MEETINGS in Multiple Myeloma
by cadie
IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione...